{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:03:18Z","timestamp":1785528198309,"version":"3.56.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA247796"],"award-info":[{"award-number":["P30CA247796"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The E.W. and Lucille Cates Memorial Fund in Leukemia Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41375-026-02963-w","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:33:05Z","timestamp":1776771185000},"page":"1793-1796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interstitial loss of heterozygosity at Chr19q13 in CD33-negative AML"],"prefix":"10.1038","volume":"40","author":[{"given":"Vivek M.","family":"Shastri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Loken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-0007","authenticated-orcid":false,"given":"Jatinder K.","family":"Lamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2963_CR1","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","volume":"32","author":"AS Gamis","year":"2014","unstructured":"Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531. J Clin Oncol. 2014;32:3021\u201332.","journal-title":"J Clin Oncol"},{"key":"2963_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","volume":"104","author":"J Lambert","year":"2019","unstructured":"Lambert J, Pautas C, Terre C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104:113\u20139.","journal-title":"Haematologica"},{"key":"2963_CR3","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986\u201396.","journal-title":"Lancet Oncol"},{"key":"2963_CR4","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","volume":"35","author":"JK Lamba","year":"2017","unstructured":"Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, et al. CD33 splicing polymorphism determines gemtuzumab ozogamicin response in De Novo acute myeloid leukemia: report from randomized phase III Children\u2019s Oncology Group trial AAML0531. J Clin Oncol. 2017;35:2674\u201382.","journal-title":"J Clin Oncol"},{"key":"2963_CR5","first-page":"PO.18.00387","volume":"3","author":"L Chauhan","year":"2019","unstructured":"Chauhan L, Shin M, Wang Y-C, Loken M, Pollard J, Aplenc R, et al. CD33_PGx6_Score predicts gemtuzumab ozogamicin response in childhood acute myeloid leukemia: a report from the Children\u2019s Oncology Group. JCO Precis Oncol. 2019;3:PO.18.00387.","journal-title":"JCO Precis Oncol"},{"key":"2963_CR6","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1080\/10428194.2019.1569232","volume":"60","author":"I Papageorgiou","year":"2019","unstructured":"Papageorgiou I, Loken MR, Brodersen LE, Gbadamosi M, Uy GL, Meshinchi S, et al. CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents. Leuk Lymphoma. 2019;60:2287\u201390.","journal-title":"Leuk Lymphoma"},{"key":"2963_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00239-022-10088-8","volume":"91","author":"C Smukowski Heil","year":"2023","unstructured":"Smukowski Heil C. Loss of heterozygosity and its importance in evolution. J Mol Evol. 2023;91:369\u201377.","journal-title":"J Mol Evol"},{"key":"2963_CR8","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s44319-024-00353-w","volume":"26","author":"A Dutta","year":"2025","unstructured":"Dutta A, Schacherer J. The dynamics of loss of heterozygosity events in genomes. EMBO Rep. 2025;26:602\u201312.","journal-title":"EMBO Rep"},{"key":"2963_CR9","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1158\/2326-6066.CIR-22-0366","volume":"10","author":"H Laubli","year":"2022","unstructured":"Laubli H, Nalle SC, Maslyar D. Targeting the Siglec-Sialic acid immune axis in cancer: current and future approaches. Cancer Immunol Res. 2022;10:1423\u201332.","journal-title":"Cancer Immunol Res"},{"key":"2963_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200353","volume":"12","author":"F Graus","year":"2025","unstructured":"Graus F, Sabater L, Gaig C, Gelpi E, Iranzo A, Dalmau JO, et al. Anti-IgLON5 disease 10 years later: what we know and what we do not know. Neurol Neuroimmunol Neuroinflamm. 2025;12:e200353.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2963_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0104-2","volume":"8","author":"Y Kumar","year":"2015","unstructured":"Kumar Y, Yang J, Hu T, Chen L, Xu Z, Xu L, et al. Massive interstitial copy-neutral loss-of-heterozygosity as evidence for cancer being a disease of the DNA-damage response. BMC Med Genomics. 2015;8:42.","journal-title":"BMC Med Genomics"},{"key":"2963_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1006\/gyno.1997.4709","volume":"66","author":"A Bicher","year":"1997","unstructured":"Bicher A, Ault K, Kimmelman A, Gershenson D, Reed E, Liang B. Loss of heterozygosity in human ovarian cancer on chromosome 19q. Gynecol Oncol. 1997;66:36\u201340.","journal-title":"Gynecol Oncol"},{"key":"2963_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/jnen\/59.6.539","volume":"59","author":"M Nakamura","year":"2000","unstructured":"Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol. 2000;59:539\u201343.","journal-title":"J Neuropathol Exp Neurol"},{"key":"2963_CR14","first-page":"1358","volume":"7","author":"J Mora","year":"2001","unstructured":"Mora J, Cheung NK, Chen L, Qin J, Gerald W. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin Cancer Res. 2001;7:1358\u201361.","journal-title":"Clin Cancer Res"},{"key":"2963_CR15","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1002\/cncr.29475","volume":"121","author":"CM Gronseth","year":"2015","unstructured":"Gronseth CM, McElhone SE, Storer BE, Kroeger KA, Sandhu V, Fero ML, et al. Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia. Cancer. 2015;121:2900\u20138.","journal-title":"Cancer"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02963-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02963-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02963-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:19:36Z","timestamp":1785521976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02963-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2963"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02963-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MRL has employment and ownership of Hematologics, Inc. JKL has equity and is scientific advisor of Almagenomics. All other authors have no competing financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}